Newron Pharmaceuticals S.p.A. (NP5.DE)
XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
As of 05:35PM CEST. Market open.
Loading interactive chart...
- Business Wire
Newron Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients
MILAN, April 30, 2024--Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients
- Business Wire
Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
MILAN, April 08, 2024--Newron presents existing evenamide study 014/015 data and future clinical development outlook for evenamide at 2024 SIRS Congress in Florence, Italy
- Business Wire
Newron Presents 2023 Financial Results and Provides 2024 Outlook
MILAN, March 19, 2024--Newron Pharmaceuticals announces 2023 year-end financial results and provides 2024 business outlook.
© 2024 Yahoo. All rights reserved.